Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Tribune Therapeutics has raised $24.8M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Tribune Therapeutics's investors include Novo Holdings, HealthCap, Innovestor, LifeArc Ventures, Industrifonden.
Tribune Therapeutics is headquartered in Stockholm, Sweden.
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Tribune Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tribune Therapeutics — Funding & Investors." VCBacked, March 26, 2025, https://www.vcbacked.co/company/tribune-therapeutics. Accessed September 2, 2026.
VCBacked. (2025). Tribune Therapeutics — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/tribune-therapeutics
{{cite web |title=Tribune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tribune-therapeutics |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated